{"title":"芬氟拉明:治疗德拉韦综合征癫痫发作的新方法。","authors":"Joanna Garcia Pierce, Divakar S Mithal","doi":"10.15844/pedneurbriefs-34-8","DOIUrl":null,"url":null,"abstract":"<p><p>Investigators for the FAiRE DS Study Group assessed the efficacy and safety of Fenfluramine for treating seizures in patients less than 18 y.o. with Dravet Syndrome in an international double-blind, placebo-controlled clinical trial. A total of 119 patients (mean age 9.0 y, 54% male) were enrolled in the study.</p>","PeriodicalId":30710,"journal":{"name":"Pediatric Neurology Briefs","volume":"34 ","pages":"8"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071945/pdf/","citationCount":"3","resultStr":"{\"title\":\"Fenfluramine: New Treatment for Seizures in Dravet Syndrome.\",\"authors\":\"Joanna Garcia Pierce, Divakar S Mithal\",\"doi\":\"10.15844/pedneurbriefs-34-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Investigators for the FAiRE DS Study Group assessed the efficacy and safety of Fenfluramine for treating seizures in patients less than 18 y.o. with Dravet Syndrome in an international double-blind, placebo-controlled clinical trial. A total of 119 patients (mean age 9.0 y, 54% male) were enrolled in the study.</p>\",\"PeriodicalId\":30710,\"journal\":{\"name\":\"Pediatric Neurology Briefs\",\"volume\":\"34 \",\"pages\":\"8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071945/pdf/\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Neurology Briefs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15844/pedneurbriefs-34-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Neurology Briefs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15844/pedneurbriefs-34-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
摘要
FAiRE DS研究组的研究人员在一项国际双盲、安慰剂对照临床试验中评估了芬氟拉明治疗18岁以下Dravet综合征患者癫痫发作的有效性和安全性。共纳入119例患者(平均年龄9.0岁，男性54%)。
Fenfluramine: New Treatment for Seizures in Dravet Syndrome.
Investigators for the FAiRE DS Study Group assessed the efficacy and safety of Fenfluramine for treating seizures in patients less than 18 y.o. with Dravet Syndrome in an international double-blind, placebo-controlled clinical trial. A total of 119 patients (mean age 9.0 y, 54% male) were enrolled in the study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
